Growth Hormone-Releasing Hormone Receptor Targeting Explored for Acute Myeloid Leukaemia Treatment

Acute myeloid leukaemia (AML) is an aggressive hematological malignancy with poor prognosis, especially in relapsed or refractory cases. Current treatments often involve intensive chemotherapy, which can have severe side effects and limited efficacy for many patients. Identifying novel therapeutic targets is crucial for improving outcomes. The growth hormone-releasing hormone receptor (GHRHR) is expressed in various cancers, including AML, and its activation can promote cell proliferation and survival, suggesting it as a potential oncogenic pathway.